Wendelboe
TL2 Member · Wakefield, UK
Keeps a personal log and shares the numbers when they are relevant, with the measurement caveats attached.
Joined 11 July 2025 · last posted 2d
95Posts here
0Topics
0Solutions
2kLikes received
1.4kLikes given
21Badges
204Days visited
4.7kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #110 · Access › International · 26 Jul 2026 · 2 likes Worth separating two things that post #106 runs together. Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where…
-
What is genuinely unknown about long-term amylin agonism Replied, post #58 · Compounds › Cagrilintide & amylin analogues · 19 Jul 2026 · 16 likes post #57 answers the question as asked. The question underneath it is different. Historical amylin analogues: pramlintide was the only long-acting amylin analogue…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #61 · Compounds › Repair & healing peptides · 17 Jul 2026 · 0 likes This follows post #58 rather than contradicting it. Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #28 · Sourcing › Regulatory · 16 Jul 2026 · 26 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #33 · Compounds › Retatrutide · 13 Jul 2026 · 0 likes This follows post #30 rather than contradicting it. The phase 2 obesity paper reported dose-dependent weight reduction of a magnitude that attracted attention. It also…
-
How shortages have affected compounding permissions Replied, post #33 · Access › Shortages · 12 Jul 2026 · 0 likes Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #53 · Compounds › Retatrutide · 11 Jul 2026 · 1 like Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in…
-
Journal club: what we got wrong in an earlier session Replied, post #71 · Evidence › Journal club · 10 Jul 2026 · 6 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #40 · Practice › Side effects · 9 Jul 2026 · 16 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #115 · Evidence › Journal club · 9 Jul 2026 · 14 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
-
Submitting a sample: the process end to end Replied, post #54 · Sourcing › Independent verification · 2 Jul 2026 · 21 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Tracking a shortage from primary sources rather than rumour Replied, post #74 · Access › Shortages · 28 Jun 2026 · 2 likes Communication from suppliers: a supplier having supply problems usually communicates them. If a supplier goes silent, that is itself information.